Skip to main content
Premium Trial:

Request an Annual Quote

CompanionDx, RegenWell Sign Deal to Bring Genomics Testing to POC

NEW YORK (GenomeWeb) – CompanionDx Reference Lab announced a deal on Monday with RegenWell Holdings to bring CompanionDx's tests to the point-of-care setting.

The deal will provide RegenWell, a Georgia-based, integrated healthcare provider, access to CompanionDx's pharmacogenomics, cancer companion diagnostics, targeted next-generation sequencing, and epigenomics testing.

"This partnership is indicative of the trend in healthcare to create synergistic relationships which enable better healthcare options for patients," CompanionDx Senior Vice President of Sales Nikko Khazana said in a statement. "Through the CompanionDx Lab and RegenWell alliance, we are expanding the opportunity to use personal genomic information in patient care and therapeutic decision-making."

Financial and other terms of the deal were not disclosed.

CompanionDx is a high-complexity CLIA-certified laboratory, and has forged deals recently with Rx Review Service and Enable Healthcare to increase the use of pharmacogenomics testing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.